EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy

Zeda Zhang, Yu-Jui Ho, Xin Fang, Minseo Kim, Marguerite Li, Wei Luan, Clemens Hinterleitner, Sascha Haubner, Friederike Kogel, Edwin C Pratt, Elif Ozcelik, José Reyes und 48 weitere

Cell · 2026-05 · 189 (10) · 2898-2917.e42

DOI: 10.1016/j.cell.2026.03.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2026-05. Verfasst von Zeda Zhang und 59 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasms, Receptors, Chimeric Antigen, Receptors, Urokinase Plasminogen Activator. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cells have transformed hematologic cancer therapy but remain limited in solid tumors by antigen heterogeneity and a suppressive, pro-fibrotic microenvironment. We previously identified the urokinase plasminogen activator receptor (uPAR) as upregulated in senescent, pro-fibrotic cells and showed that uPAR-directed CAR T cells could safely reverse fibrosis in mice. Integrative analyses now reveal that uPAR is broadly expressed in solid tumors enriched for TP53 and RAS pathway mutations. These tumors adopt a progenitor-like state supported by a niche of uPAR-positive stromal cells with senescence features. Human uPAR CAR T cells eliminate tumor cells and their stromal support, induce durable regressions across diverse models, eradicate systemic metastases, and are potentiated by senescence-inducing therapies. Importantly, these cells achieve robust antitumor activity without sustained myelosuppression in mice reconstituted with human immune systems. Together, these findings establish uPAR as a broadly applicable CAR T target capable of overcoming major barriers in solid tumor therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenReceptors, Urokinase Plasminogen ActivatorTumor MicroenvironmentHumansCellular SenescenceT-LymphocytesTumor Suppressor Protein p53FemaleAnimalsMiceMice, Inbred C57BLMice, NudeMice, Inbred NODMaleOvarian NeoplasmsCell Line, TumorXenograft Model Antitumor Assays

Stichwörter der Autor:innen

CAR T cellsfibrosisp53senescencesenolytictumor microenvironmentuPAR

Substanzen

PLAUR protein, humanReceptors, Chimeric AntigenReceptors, Urokinase Plasminogen ActivatorTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.
  • Columbia Initiative in Cell Engineering and Therapy, Department of Medicine, Columbia University, New York, NY, USA.
  • Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • NIA NIH HHS
  • Pershing Square Sohn Cancer Research Alliance
  • Damon Runyon Cancer Research Foundation
  • Cycle for Survival
  • The Mark Foundation for Cancer Research
  • American Federation for Aging Research

Zitieren

APA

Zhang, Z., Ho, Y. J., Fang, X., Kim, M., Li, M., Luan, W., Hinterleitner, C., Haubner, S., Kogel, F., Pratt, E. C., Ozcelik, E., Reyes, J., Jiang, Q., Yang, V. W., Chen, Y. J., Wang, T., Liu, H., Hu, H., Zhuang, X., …, & Zamarin, D. (2026). A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell, 189(10), 2898-2917.e42. https://doi.org/10.1016/j.cell.2026.03.002

Vancouver

Zhang Z, Ho YJ, Fang X, Kim M, Li M, Luan W, et al. A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell. 2026;189(10):2898-2917.e42. doi:10.1016/j.cell.2026.03.002

BibTeX
@article{Zhang2026,
  author = {Zhang, Zeda and Ho, Yu-Jui and Fang, Xin and Kim, Minseo and Li, Marguerite and Luan, Wei and Hinterleitner, Clemens and Haubner, Sascha and Kogel, Friederike and Pratt, Edwin C and Ozcelik, Elif and Reyes, José and Jiang, Qingwen and Yang, Vincent W and Chen, Yu-Jung and Wang, Tao and Liu, Haijiao and Hu, Haonan and Zhuang, Xueqian and Park, Jin and Paffenholz, Stella V and Chen, Kevin and Chang, Qing and Kulick, Amanda and Zhang, Jing and Chan, Eric and Rosiek, Eric and Fan, Ning and Williams, Riley A and Wang, Adam C and Freeman, Samuel and Tian, Sha and Gunset, Gertrude and Garcia Angus, Andreina and Lecomte, Nicolas and Yildirim, Selma Yeni and Ali, Emily and Wu, Michelle and Miranda, Ileana C and Antonescu, Cristina R and Basturk, Olca and Tarcan, Zeynep and Rekhtman, Natasha and Wilson, Christina and Basar, Merve and Sauter, Jennifer L and Al-Ahmadie, Hikmat A and Singer, Samuel and Iacobuzio-Donahue, Christine and Rudin, Charles and de Stanchina, Elisa and Ganesh, Karuna and Romesser, Paul B and Weigelt, Britta and Huh, Dan Dongeun and Leibold, Josef and Feucht, Judith and Vázquez-García, Ignacio and Bott, Matthew J and Zamarin, Dmitriy},
  title = {A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy},
  journal = {Cell},
  year = {2026},
  volume = {189},
  number = {10},
  pages = {2898--2917.e42},
  doi = {10.1016/j.cell.2026.03.002}
}
Kostenlos starten →